Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 5Thoracic 1Lymphoid 1Gastrointestinal 1

Conditions

Muscular Atrophy 1Lymphoma, Non-Hodgkin 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × ostarine × Lymphoid × Clear all
NCT00467844 2014-07-11

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

GTx

Phase 2 Completed
159 enrolled 11 charts
GastrointestinalLymphoidThoracic

Cachexia, Carcinoma, Non-Small-Cell Lung, Lymphoma, Non-Hodgkin, Muscular Atrophy, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡